Invention Grant
- Patent Title: Enhanced oligonucleotides for inhibiting RTEL1 expression
-
Application No.: US17590754Application Date: 2022-02-01
-
Publication No.: US11898145B2Publication Date: 2024-02-13
- Inventor: Erik Funder , Natascha Hruschka , Susanne Kammler , Erich Koller , Brian Leonard , Souphalone Luangsay , Susanne Mohr , Tobias Nilsson , Søren Ottosen , Lykke Pedersen , Søren V. Rasmussen , Steffen Schmidt , Sabine Sewing , Daniel Turley , Johanna Marie Walther
- Applicant: HOFFMANN-LA ROCHE INC.
- Applicant Address: US NJ Little Falls
- Assignee: Hoffmann-La Roche Inc.
- Current Assignee: Hoffmann-La Roche Inc.
- Current Assignee Address: US NJ Little Falls
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: EP 154701 2021.02.02 EP 207002 2021.11.08
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61P31/20 ; A61K31/7088
Abstract:
The present disclosure provides antisense oligonucleotides targeting Regulator of telomere elongation helicase 1 (RTEL1). The disclosure also provides, enhanced antisense oligonucleotides targeting RTEL1 for use in treating and/or preventing a hepatitis B virus (HBV) infection. Also disclosed are pharmaceutical compositions and their use.
Public/Granted literature
- US20220251556A1 ENHANCED OLIGONUCLEOTIDES FOR INHIBITING RTEL1 EXPRESSION Public/Granted day:2022-08-11
Information query
IPC分类:
